Global Diabetic Retinopathy Market 2020 Research Forecast 2026

Published On: Dec 2019

Format: PDF

Publisher: QY Research

Pages: 112

Report ID: 86489

Diabetic retinopathy is a disorder of the eye that damages the blood vessels of the retina. The retina is the light-sensitive inner surface of the eye on which images are formed. Long-term diabetes affects the retina as high blood glucose levels can damage the tiny blood vessels in the retina. Diabetic retinopathy is broadly classified into non-proliferative diabetic retinopathy and proliferative retinopathy. Treatment for diabetic retinopathy depends on the stage of the disease and is directed toward slowing down or stopping the progression of the disease.
Laser surgery, injection of corticosteroids or anti-VEGF drugs into the eye, and vitrectomy are some of the available treatments. One feature of diabetic retinopathy is diabetic macular edema. This is a serious medical condition involving leakage of fluid from the minute, delicate, and previously injured blood vessels located at the back of the eye, which then collects in the macula. This results in inflammation of tissue and blurry vision.
In 2020, the global Diabetic Retinopathy market size was xx million US$ and it is expected to reach xx million US$ by the end of 2026, with a CAGR of xx% during 2020-2026.

This report focuses on the global Diabetic Retinopathy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Diabetic Retinopathy development in United States, Europe and China.

The key players covered in this study
Bayer
F. Hoffmann-La Roche
Novartis
Regeneron Pharmaceuticals
 Actavis
Alimera Sciences
Ampio Pharmaceuticals
Antisense Therapeutics
BCN Peptides
Boehringer Ingelheim
Glycadia
iCo Therapeutics
Isis Pharmaceuticals
Kowa Group
Lpath
Numoda Capital
Ohr Pharmaceutical
OPKO Health
Parexel International
Promedior
pSivida
Quark Pharmaceuticals
R-Tech Ueno
Sirnaomics
ThromboGenics 

Market segment by Type, the product can be split into
Laser surgery
Injection of corticosteroids
Anti-VEGF drugs into the eye
Vitrectomy

Market segment by Application, split into
Hospitals
Clinics and laboratories
Others

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Diabetic Retinopathy status, future forecast, growth opportunity, key market and key players.
To present the Diabetic Retinopathy development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Diabetic Retinopathy are as follows:
History Year: 2014-2018
Base Year: 2019
Estimated Year: 2019
Forecast Year 2020 to 2026
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Diabetic Retinopathy Market Size Growth Rate by Type (2015-2026)
1.4.2 Laser surgery
1.4.3 Injection of corticosteroids
1.4.4 Anti-VEGF drugs into the eye
1.4.5 Vitrectomy
1.5 Market by Application
1.5.1 Global Diabetic Retinopathy Market Share by Application (2015-2026)
1.5.2 Hospitals
1.5.3 Clinics and laboratories
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Diabetic Retinopathy Market Size
2.2 Diabetic Retinopathy Growth Trends by Regions
2.2.1 Diabetic Retinopathy Market Size by Regions (2015-2026)
2.2.2 Diabetic Retinopathy Market Share by Regions (2015-2020)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Diabetic Retinopathy Market Size by Manufacturers
3.1.1 Global Diabetic Retinopathy Revenue by Manufacturers (2015-2020)
3.1.2 Global Diabetic Retinopathy Revenue Market Share by Manufacturers (2015-2020)
3.1.3 Global Diabetic Retinopathy Market Concentration Ratio (CR5 and HHI)
3.2 Diabetic Retinopathy Key Players Head office and Area Served
3.3 Key Players Diabetic Retinopathy Product/Solution/Service
3.4 Date of Enter into Diabetic Retinopathy Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Diabetic Retinopathy Market Size by Type (2015-2020)
4.2 Global Diabetic Retinopathy Market Size by Application (2015-2020)

5 United States
5.1 United States Diabetic Retinopathy Market Size (2015-2020)
5.2 Diabetic Retinopathy Key Players in United States
5.3 United States Diabetic Retinopathy Market Size by Type
5.4 United States Diabetic Retinopathy Market Size by Application

6 Europe
6.1 Europe Diabetic Retinopathy Market Size (2015-2020)
6.2 Diabetic Retinopathy Key Players in Europe
6.3 Europe Diabetic Retinopathy Market Size by Type
6.4 Europe Diabetic Retinopathy Market Size by Application

7 China
7.1 China Diabetic Retinopathy Market Size (2015-2020)
7.2 Diabetic Retinopathy Key Players in China
7.3 China Diabetic Retinopathy Market Size by Type
7.4 China Diabetic Retinopathy Market Size by Application

8 Japan
8.1 Japan Diabetic Retinopathy Market Size (2015-2020)
8.2 Diabetic Retinopathy Key Players in Japan
8.3 Japan Diabetic Retinopathy Market Size by Type
8.4 Japan Diabetic Retinopathy Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Diabetic Retinopathy Market Size (2015-2020)
9.2 Diabetic Retinopathy Key Players in Southeast Asia
9.3 Southeast Asia Diabetic Retinopathy Market Size by Type
9.4 Southeast Asia Diabetic Retinopathy Market Size by Application

10 India
10.1 India Diabetic Retinopathy Market Size (2015-2020)
10.2 Diabetic Retinopathy Key Players in India
10.3 India Diabetic Retinopathy Market Size by Type
10.4 India Diabetic Retinopathy Market Size by Application

11 Central & South America
11.1 Central & South America Diabetic Retinopathy Market Size (2015-2020)
11.2 Diabetic Retinopathy Key Players in Central & South America
11.3 Central & South America Diabetic Retinopathy Market Size by Type
11.4 Central & South America Diabetic Retinopathy Market Size by Application

12 International Players Profiles
12.1 Bayer
12.1.1 Bayer Company Details
12.1.2 Company Description and Business Overview
12.1.3 Diabetic Retinopathy Introduction
12.1.4 Bayer Revenue in Diabetic Retinopathy Business (2015-2020)
12.1.5 Bayer Recent Development
12.2 F. Hoffmann-La Roche
12.2.1 F. Hoffmann-La Roche Company Details
12.2.2 Company Description and Business Overview
12.2.3 Diabetic Retinopathy Introduction
12.2.4 F. Hoffmann-La Roche Revenue in Diabetic Retinopathy Business (2015-2020)
12.2.5 F. Hoffmann-La Roche Recent Development
12.3 Novartis
12.3.1 Novartis Company Details
12.3.2 Company Description and Business Overview
12.3.3 Diabetic Retinopathy Introduction
12.3.4 Novartis Revenue in Diabetic Retinopathy Business (2015-2020)
12.3.5 Novartis Recent Development
12.4 Regeneron Pharmaceuticals
12.4.1 Regeneron Pharmaceuticals Company Details
12.4.2 Company Description and Business Overview
12.4.3 Diabetic Retinopathy Introduction
12.4.4 Regeneron Pharmaceuticals Revenue in Diabetic Retinopathy Business (2015-2020)
12.4.5 Regeneron Pharmaceuticals Recent Development
12.5  Actavis
12.5.1  Actavis Company Details
12.5.2 Company Description and Business Overview
12.5.3 Diabetic Retinopathy Introduction
12.5.4  Actavis Revenue in Diabetic Retinopathy Business (2015-2020)
12.5.5  Actavis Recent Development
12.6 Alimera Sciences
12.6.1 Alimera Sciences Company Details
12.6.2 Company Description and Business Overview
12.6.3 Diabetic Retinopathy Introduction
12.6.4 Alimera Sciences Revenue in Diabetic Retinopathy Business (2015-2020)
12.6.5 Alimera Sciences Recent Development
12.7 Ampio Pharmaceuticals
12.7.1 Ampio Pharmaceuticals Company Details
12.7.2 Company Description and Business Overview
12.7.3 Diabetic Retinopathy Introduction
12.7.4 Ampio Pharmaceuticals Revenue in Diabetic Retinopathy Business (2015-2020)
12.7.5 Ampio Pharmaceuticals Recent Development
12.8 Antisense Therapeutics
12.8.1 Antisense Therapeutics Company Details
12.8.2 Company Description and Business Overview
12.8.3 Diabetic Retinopathy Introduction
12.8.4 Antisense Therapeutics Revenue in Diabetic Retinopathy Business (2015-2020)
12.8.5 Antisense Therapeutics Recent Development
12.9 BCN Peptides
12.9.1 BCN Peptides Company Details
12.9.2 Company Description and Business Overview
12.9.3 Diabetic Retinopathy Introduction
12.9.4 BCN Peptides Revenue in Diabetic Retinopathy Business (2015-2020)
12.9.5 BCN Peptides Recent Development
12.10 Boehringer Ingelheim
12.10.1 Boehringer Ingelheim Company Details
12.10.2 Company Description and Business Overview
12.10.3 Diabetic Retinopathy Introduction
12.10.4 Boehringer Ingelheim Revenue in Diabetic Retinopathy Business (2015-2020)
12.10.5 Boehringer Ingelheim Recent Development
12.11 Glycadia
12.12 iCo Therapeutics
12.13 Isis Pharmaceuticals
12.14 Kowa Group
12.15 Lpath
12.16 Numoda Capital
12.17 Ohr Pharmaceutical
12.18 OPKO Health
12.19 Parexel International
12.20 Promedior
12.21 pSivida
12.22 Quark Pharmaceuticals
12.23 R-Tech Ueno
12.24 Sirnaomics
12.25 ThromboGenics 

13 Market Forecast 2020-2026
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2020-2026)
13.10 Market Size Forecast by Application (2020-2026)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details